Literature DB >> 2255665

Effects of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazam.

H Bun1, S Monjanel-Mouterde, F Noel, A Durand, J P Cano.   

Abstract

The authors monitored the plasma levels of clobazam (CLO) and its principal metabolite, N-desmethylclobazam (NCLO) during chronic treatment of more than 400 epileptic patients receiving different co-medications, such as phenytoin (PH), carbamazepine (CBZ), sodium valproate (VPA) and phenobarbital (PB). This study investigated the influence of age and antiepileptic drugs on plasma levels of CLO and NCLO. Plasma concentrations measured 3 hr after morning administration of CLO varied from 30 to 700 [formula; see text] for CLO, and from 160 to 7000 [formula; see text] for NCLO. Plasma levels of CLO were higher in patients aged 20-30 years. NCLO concentrations increased with age up to 20 years. Coadministered antiepileptic compounds significantly decreased maximal plasma levels of CLO. Moreover, PH and CBZ a significantly increased the plasma levels of NCLO. Results on the influence of CBZ on CLO kinetics were confirmed in a group of ten patients receiving PB and VPA and later PB, VPA and CBZ as CLO associated drugs. The influence of VPA on the pharmacokinetics parameters of CLO was also evaluated in a patient in the latter group.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2255665     DOI: 10.1111/j.1600-0773.1990.tb00799.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  11 in total

Review 1.  GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam.

Authors:  Raman Sankar
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

Review 2.  Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation.

Authors:  P Glue; C R Banfield; J L Perhach; G G Mather; J K Racha; R H Levy
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

Review 3.  Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies.

Authors:  Jose de Leon; Edoardo Spina; Francisco J Diaz
Journal:  Ther Drug Monit       Date:  2013-02       Impact factor: 3.681

Review 4.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

5.  PharmGKB summary: clobazam pathway, pharmacokinetics.

Authors:  Rachel Huddart; J Steven Leeder; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2018-04       Impact factor: 2.089

Review 6.  Clobazam.

Authors:  Yu-tze Ng; Stephen D Collins
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

7.  Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy.

Authors:  Yoshiaki Yamamoto; Yukitoshi Takahashi; Katsumi Imai; Masaaki Takahashi; Masahiko Nakai; Yushi Inoue; Yoshiyuki Kagawa
Journal:  Eur J Clin Pharmacol       Date:  2014-07-22       Impact factor: 2.953

8.  Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid.

Authors:  Vincent Jullien; Stéphanie Chhun; Elisabeth Rey; Olivier Dulac; Michel Tod; Catherine Chiron; Gérard Pons
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

9.  Persistent Hypersomnolence Following Clobazam in a Child With Epilepsy and Undiagnosed CYP2C19 Polymorphism.

Authors:  Katherine E Hamilton; Chasity M Shelton; James Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2020

Review 10.  Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndrome.

Authors:  Michele A Faulkner
Journal:  Ther Clin Risk Manag       Date:  2015-06-08       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.